GlaxoSmithKline (GSK) has entered into a global strategic collaboration with the Merck group for an immunotherapy candidate M7824 (bintrafusp alfa) in difficult-to-treat cancers.
As part of the deal, which is valued at approximately €3.7bn ($4.2bn), the companies will jointly develop and commercialise the product for multiple indications.
Go deeper with GlobalData
M7824 is Merck’s investigational bifunctional fusion protein compound that acts simultaneously on transforming growth factor-β (TGF-β) trap and an anti-programmed cell death ligand-1 (PD-L1).
Both TGF-β and PD-L1 are immuno-suppressive pathways used by tumours to avoid the body’s immune system. Targeting these pathways is expected to control tumour growth.
The immunotherapy candidate is currently in clinical development as a monotherapy and in combination with other GSK and Merck products.
Eight immuno-oncology studies are ongoing or set to be initiated this year, including trials for non-small cell lung and biliary tract cancers.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGSK chief scientific officer and R&D president Hal Barron said: “Despite recent medical advances, many patients with difficult-to-treat cancers don’t currently benefit from immuno-oncology therapies leaving them with limited treatment options.
“M7824 brings together two different biological functions in a single molecule and we have observed encouraging clinical results in treating certain cancer patients, particularly those people with non-small cell lung cancer.”
Under the terms of the alliance, Merck will receive an upfront payment of €300m from GSK, along with up to €500m in potential development milestones triggered by data from the lung cancer programme.
Merck is additionally eligible for up to €2.9bn based on future approval and commercial milestones. The partners will equally share all profits and costs on a global basis.
Merck Healthcare CEO Belén Garijo said: “Our bifunctional fusion protein M7824 has the potential to bring new answers to patients living with cancer. Together with GSK we aim to drive a paradigm shift in the treatment of cancer as the leader in this novel class of immunotherapies.
“We now look forward to harnessing the full potential of M7824 across a broad range of cancer indications as we continue to advance our oncology portfolio.”
The partnership is in line with Merck’s oncology R&D strategy aimed at advancing its clinical stage assets, while GSK expects to boost its pharmaceuticals pipeline.
GSK recently acquired US-based oncology-focused biopharmaceutical company Tesaro to strengthen its pharmaceutical business.
